[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Outlook 2018-2025

August 2018 | 136 pages | ID: GFC938BBCC4EN
99Strategy

US$ 4,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
REPORT SNAPSHOT

Key Content of Chapters (Including and can be customized, report is a semifinished version, and it takes 48-72 hours to upgrade)

Part 1:
Terminology Definition, Industry Chain,Industry Dynamics & Regulations and Global Market Overview
Part 2:
Upstream (Raw Materials / Components) & Manufacturing (Procurement Methods & Channels and Cost), Major Regional Production Overview and Trade Flow
Part 3:
Product Segment Overview and Market Status
Part 4:
Application / End-User Segment Overview and Market Status
Part 5:
Region Segment Overview and Market Status
Part 6:
Product & Application Segment Production & Demand by Region
Part 7:
Market Forecast by Product, Application & Region
Part 8:
Company information, Products & Services and Business Operation (Sales, Cost, Margin etc.)
Part 9:
Market Competition and Environment for New Entrants
Part 10:
Conclusion

Market Segment as follows:

Key Companies
  • Astellas Pharma
  • Eli Lilly
  • GlaxoSmithKline
  • Sanofi
  • ADC Therapeutics
  • Bayer HealthCare
  • Bristol-Myers Squibb
  • Valeant Pharmaceuticals
  • Endo Pharmaceuticals
  • Foresee Pharmaceuticals
  • Madrigal Pharmaceuticals
  • Merck
  • Novartis
  • Spectrum Pharmaceuticals
  • Takeda Pharmaceuticals
  • Teva
  • Advaxis
  • ANI Pharmaceuticals
  • BHR Pharma
Market by Type
  • Alpha-blocker
  • Phosphodiesterase Type-5 Inhibitors
  • 5-alpha-Reductase Inhibitors
Market by Application
  • Hospitals
  • Clinics
  • Others
PART 1 INDUSTRY OVERVIEW (200 USD)

1.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry
  1.1.1 Market Development
  1.1.2 Terminology Definition in the Report
    1.1.2.1 Production
    1.1.2.2 Demand
    1.1.2.3 Sales Revenue
    1.1.2.4 Ex-factory Price & Sales Price
    1.1.2.5 Cost
    1.1.2.6 Gross Margin
1.2 Products & Services Scope
1.3 Industry Chain
1.4 Industry Dynamics & Regulations
1.5 Global Market Overview

PART 2 UPSTREAM & PRODUCTION (200 USD)

2.1 Raw Materials / Components
2.2 Procurement Methods & Channels
2.3 Cost Structure & Manufacturing
2.4 Industry Capacity
2.5 Production Distribution by Geography
  2.5.1 Production in Major Regions / Countries
  2.5.2 Trade Flow Overview

PART 3 PRODUCT SEGMENT (400 USD)

3.1 Introduction by Type
  3.1.1 Alpha-blocker
  3.1.2 Phosphodiesterase Type-5 Inhibitors
  3.1.3 5-alpha-Reductase Inhibitors
3.2 Market Status

PART 4 APPLICATION / END-USER SEGMENT (400 USD)

4.1 Introduction by Application
  4.1.1 Hospitals
  4.1.2 Clinics
  4.1.3 Others
4.2 Market Status

PART 5 REGIONAL MARKET (600 USD)

5.1 Market Overview
5.2 by Region
  5.2.1 North America
    5.2.1.1 United States Market Size and Growth (2015-2018E)
    5.2.1.2 Canada Market Size and Growth (2015-2018E)
    5.2.1.3 Mexico Market Size and Growth (2015-2018E)
  5.2.2 Europe
    5.2.2.1 Germany Market Size and Growth (2015-2018E)
    5.2.2.2 UK Market Size and Growth (2015-2018E)
    5.2.2.3 France Market Size and Growth (2015-2018E)
    5.2.2.4 Italy Market Size and Growth (2015-2018E)
    5.2.2.5 Spain Market Size and Growth (2015-2018E)
    5.2.2.6 Netherlands Market Size and Growth (2015-2018E)
    5.2.2.7 Poland Market Size and Growth (2015-2018E)
    5.2.2.8 Belgium Market Size and Growth (2015-2018E)
    5.2.2.9 Sweden Market Size and Growth (2015-2018E)
    5.2.2.10 Austria Market Size and Growth (2015-2018E)
    5.2.2.11 Denmark Market Size and Growth (2015-2018E)
    5.2.2.12 Switzerland Market Size and Growth (2015-2018E)
    5.2.2.13 Russia Market Size and Growth (2015-2018E)
  5.2.3 Asia-Pacific
    5.2.3.1 China Market Size and Growth (2015-2018E)
    5.2.3.2 India Market Size and Growth (2015-2018E)
    5.2.3.3 Japan Market Size and Growth (2015-2018E)
    5.2.3.4 Korea Market Size and Growth (2015-2018E)
    5.2.3.5 Australia Market Size and Growth (2015-2018E)
    5.2.3.6 Indonesia Market Size and Growth (2015-2018E)
    5.2.3.7 Thailand Market Size and Growth (2015-2018E)
    5.2.3.8 Malaysia Market Size and Growth (2015-2018E)
    5.2.3.9 Singapore Market Size and Growth (2015-2018E)
    5.2.3.10 Philippines Market Size and Growth (2015-2018E)
  5.2.4 South America
    5.2.4.1 Brazil Market Size and Growth (2015-2018E)
    5.2.4.2 Argentina Market Size and Growth (2015-2018E)
    5.2.4.3 Columbia Market Size and Growth (2015-2018E)
    5.2.4.4 Chile Market Size and Growth (2015-2018E)
    5.2.4.5 Peru Market Size and Growth (2015-2018E)
    5.2.4.6 Puerto Rico Market Size and Growth (2015-2018E)
    5.2.4.7 Ecuador Market Size and Growth (2015-2018E)
  5.2.5 Middle East
    5.2.5.1 Saudi Arabia Market Size and Growth (2015-2018E)
    5.2.5.2 Iran Market Size and Growth (2015-2018E)
    5.2.5.3 UAE Market Size and Growth (2015-2018E)
    5.2.5.4 Oman Market Size and Growth (2015-2018E)
    5.2.5.5 Kuwait Market Size and Growth (2015-2018E)
    5.2.5.6 Iraq Market Size and Growth (2015-2018E)
    5.2.5.7 Turkey Market Size and Growth (2015-2018E)
  5.2.6 Africa
    5.2.6.1 South Africa Market Size and Growth (2015-2018E)
    5.2.6.2 Egypt Market Size and Growth (2015-2018E)
    5.2.6.3 Nigeria Market Size and Growth (2015-2018E)
    5.2.6.4 Algeria Market Size and Growth (2015-2018E)
    5.2.6.5 Angola Market Size and Growth (2015-2018E)
    5.2.6.6 Morocco Market Size and Growth (2015-2018E)
    5.2.6.7 Sudan Market Size and Growth (2015-2018E)

PART 6 MARKET SUBDIVISION (800 USD)

6.1 Regional Production
  6.1.1 Production by Type
    6.1.1.1 Alpha-blocker Production by Region
    6.1.1.2 Phosphodiesterase Type-5 Inhibitors Production by Region
    6.1.1.3 5-alpha-Reductase Inhibitors Production by Region
  6.1.2 Production by Application
    6.1.2.1 Hospitals Production by Region
    6.1.2.2 Clinics Production by Region
    6.1.2.3 Others Production by Region
6.2 Regional Demand
  6.2.1 Demand by Type
    6.2.1.1 Alpha-blocker Demand by Region
    6.2.1.2 Phosphodiesterase Type-5 Inhibitors Demand by Region
    6.2.1.3 5-alpha-Reductase Inhibitors Demand by Region
  6.2.2 Demand by Application
    6.2.2.1 Hospitals Demand by Region
    6.2.2.2 Clinics Demand by Region
    6.2.2.3 Others Demand by Region

PART 7 MARKET FORECAST (200 USD)

7.1 Global Forecast
7.2 Forecast by Type
7.3 Forecast by Application
7.4 Forecast by Region

PART 8 KEY COMPANIES LIST (600 USD)

8.1 Astellas Pharma
  8.1.2 Company Information
  8.1.2 Products & Services
  8.1.3 Business Operation
8.2 Eli Lilly
  8.2.1 Company Information
  8.2.2 Products & Services
  8.2.3 Business Operation
8.3 GlaxoSmithKline
  8.3.1 Company Information
  8.3.2 Products & Services
  8.3.3 Business Operation
8.4 Sanofi
  8.4.1 Company Information
  8.4.2 Products & Services
  8.4.3 Business Operation
8.5 ADC Therapeutics
  8.5.1 Company Information
  8.5.2 Products & Services
  8.5.3 Business Operation
8.6 Bayer HealthCare
  8.6.1 Company Information
  8.6.2 Products & Services
  8.6.3 Business Operation
8.7 Bristol-Myers Squibb
  8.7.1 Company Information
  8.7.2 Products & Services
  8.7.3 Business Operation
8.8 Valeant Pharmaceuticals
  8.8.1 Company Information
  8.8.2 Products & Services
  8.8.3 Business Operation
8.9 Endo Pharmaceuticals
  8.9.1 Company Information
  8.9.2 Products & Services
  8.9.3 Business Operation
8.10 Foresee Pharmaceuticals
  8.10.1 Company Information
  8.10.2 Products & Services
  8.10.3 Business Operation
8.11 Madrigal Pharmaceuticals
8.12 Merck
8.13 Novartis
8.14 Spectrum Pharmaceuticals
8.15 Takeda Pharmaceuticals
8.16 Teva
8.17 Advaxis
8.18 ANI Pharmaceuticals
8.19 BHR Pharma

PART 9 COMPANY COMPETITION (500 USD)

9.1 Market by Company
9.2 Price & Gross Margin
9.3 Competitive Environment for New Entrants
  9.3.1 Michael Porter's Five Forces Model
  9.3.2 SWOT

PART 10 RESEARCH CONCLUSION (100 USD)

LIST OF TABLES

Table Benign Prostatic Hyperplasia (BPH) Drugs Industry Dynamics & Regulations List
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue, Cost and Margin, 2015-2018E
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type 2015-2018E, in USD Million
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Application 2015-2018E, in USD Million
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Application 2015-2018E, in Volume
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market by Region 2015-2018E, in USD Million
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Region in 2018, in USD Million
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market by Region 2015-2018E, in Volume
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Region in 2018, in Volume
Table Alpha-blocker Production Value by Region 2015-2018E, in USD Million
Table Alpha-blocker Production Volume by Region 2015-2018E, in Volume
Table Phosphodiesterase Type-5 Inhibitors Production Value by Region 2015-2018E, in USD Million
Table Phosphodiesterase Type-5 Inhibitors Production Volume by Region 2015-2018E, in Volume
Table 5-alpha-Reductase Inhibitors Production Value by Region 2015-2018E, in USD Million
Table 5-alpha-Reductase Inhibitors Production Volume by Region 2015-2018E, in Volume
Table Hospitals Production Value by Region 2015-2018E, in USD Million
Table Hospitals Production Volume by Region 2015-2018E, in Volume
Table Clinics Production Value by Region 2015-2018E, in USD Million
Table Clinics Production Volume by Region 2015-2018E, in Volume
Table Others Production Value by Region 2015-2018E, in USD Million
Table Others Production Volume by Region 2015-2018E, in Volume
Table Alpha-blocker Market Size by Region 2015-2018E, in USD Million
Table Alpha-blocker Market Size by Region 2015-2018E, in Volume
Table Phosphodiesterase Type-5 Inhibitors Market Size by Region 2015-2018E, in USD Million
Table Phosphodiesterase Type-5 Inhibitors Market Size by Region 2015-2018E, in Volume
Table 5-alpha-Reductase Inhibitors Market Size by Region 2015-2018E, in USD Million
Table 5-alpha-Reductase Inhibitors Market Size by Region 2015-2018E, in Volume
Table Hospitals Market Size by Region 2015-2018E, in USD Million
Table Hospitals Market Size by Region 2015-2018E, in Volume
Table Clinics Market Size by Region 2015-2018E, in USD Million
Table Clinics Market Size by Region 2015-2018E, in Volume
Table Others Market Size by Region 2015-2018E, in USD Million
Table Others Market Size by Region 2015-2018E, in Volume
Table GlobalBenign Prostatic Hyperplasia (BPH) Drugs Forecast by Type 2019F-2025F, in USD Million
Table Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type 2019F-2025F, in Volume
Table Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Application / End-User 2019F-2025F, in USD Million
Table Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Application / End-User 2019F-2025F, in Volume
Table Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Region 2019F-2025F, in USD Million
Table Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Region 2019F-2025F, in Volume
Table Astellas Pharma Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Astellas Pharma
Table Eli Lilly Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Eli Lilly
Table GlaxoSmithKline Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of GlaxoSmithKline
Table Sanofi Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Sanofi
Table ADC Therapeutics Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of ADC Therapeutics
Table Bayer HealthCare Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Bayer HealthCare
Table Bristol-Myers Squibb Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Bristol-Myers Squibb
Table Valeant Pharmaceuticals Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Valeant Pharmaceuticals
Table Endo Pharmaceuticals Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Endo Pharmaceuticals
Table Foresee Pharmaceuticals Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Foresee Pharmaceuticals
Table Madrigal Pharmaceuticals Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Madrigal Pharmaceuticals
Table Merck Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Merck
Table Novartis Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Novartis
Table Spectrum Pharmaceuticals Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Spectrum Pharmaceuticals
Table Takeda Pharmaceuticals Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Takeda Pharmaceuticals
Table Teva Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Teva
Table Advaxis Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Advaxis
Table ANI Pharmaceuticals Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of ANI Pharmaceuticals
Table BHR Pharma Information
Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of BHR Pharma
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue by Company 2015-2017, in USD Million
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Company 2015-2017, in Volume
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Company in 2018, in Volume

LIST OF FIGURES

Figure Benign Prostatic Hyperplasia (BPH) Drugs Picture
Figure Benign Prostatic Hyperplasia (BPH) Drugs Industry Chain Diagram
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue 2015-2018E, in USD Million
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume 2015-2018E, in Volume
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type 2015-2018E, in Volume
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in USD Million
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in Volume
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in USD Million
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in Volume
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in USD Million
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in Volume
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in USD Million
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in Volume
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in USD Million
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in Volume
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in USD Million
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in Volume
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue Forecast 2019F-2025F, in USD Million
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Forecast 2019F-2025F, in Volume
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Price Forecast 2019F-2025F
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Gross Margin Forecast 2019F-2025F
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue by Company in 2018, in USD Million
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Company in 2018
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Gross Margin by Company in 2018

More Publications

Need Help?

Ask a Question

Market Reports

All Categories